Results 51 to 60 of about 4,596,646 (261)

An Evaluation of Anticoagulant Therapy

Cardiology, 1952
Abstract 1.1. During the past decade the indications for anticoagulant therapy have been clarified. They are listed herein. 2.2. In view of the reduction in both death rate and in the incidence of thromboembolic complications following coronary thrombosis with myocardial infarction with the use of anticoagulants in mild and moderately severe cases,
openaire   +4 more sources

New concepts for anticoagulant therapy in persons with hemophilia.

Blood, 2016
To the editor: The challenging issue of anticoagulant therapy in patients with inherited bleeding disorders was highlighted by Martin and Key in a recent article in Blood .[1][1] In this field of limited evidence, expert opinions are of importance for ...
R. Schutgens, J. F. van der Heijden, E. Mauser-Bunschoten, P. Mannucci   +3 more
semanticscholar   +1 more source

Prevention of venous thromboembolism after hip and knee replacement among older adults [PDF]

, 2017
BACKGROUND: Venous thromboembolism (VTE) after total hip and knee replacement is a major patient safety threat, and pharmacologic prophylaxis is generally recommended. However, clinicians disagree on the optimal prophylaxis agent.
Ko, Darae
core  

Antithrombotic therapy with rivaroxaban in five patients with paroxysmal nocturnal haemoglobinuria and thrombotic events [PDF]

, 2018
Five patients with paroxysmal nocturnal haemoglobinuria and thrombotic complications under oral antithrombotic treatment with vitamin K antagonist were switched to receive the direct oral anticoagulant rivaroxaban an factor Xa inhibitor.
Cafolla, Arturo, Chiarotti, Flavia, Dragoni, Francesco, Iori, Anna Paola, La Rocca, Ursula   +4 more
core   +1 more source

Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Chest, 2012
BACKGROUND The objective of this article is to summarize the published literature concerning the pharmacokinetics and pharmacodynamics of oral anticoagulant drugs that are currently available for clinical use and other aspects related to their management.
W. Ageno, A. Gallus, A. Wittkowsky, M. Crowther, E. Hylek, G. Palareti   +5 more
semanticscholar   +1 more source

The clinical effectiveness and cost-effectiveness of point-of-care tests (CoaguChek system, INRatio2 PT/INR monitor and ProTime Microcoagulation system) for the self-monitoring of the coagulation status of people receiving long-term vitamin K antagonist therapy, compared with standard UK practice : systematic review and economic evaluation [PDF]

, 2015
Funding The National Institute for Health Research Health Technology Assessment programme.Peer reviewedPublisher ...
, , , , , , , , , , , , , , , , , , , , Ahmad, Ansell, Ascione, Azarnoush, Bauman, Bauman, Bauman, Bayer, Bereznicki, Bloomfield, Braun, Briggs, Bronnum-Hansen, Brown, Cayley, Christensen, Christensen, Christensen, Christensen, Christensen, Christensen, Connock, Connolly, Cromheecke, Curtis, Dauphin, DeWilde, Dorman, Drummond, Dunning, Edwards, Eitz, Fitzmaurice, Fitzmaurice, Fitzmaurice, Friberg, Friberg, Fuster, Gadisseur, Gadisseur, Gailly, Gallagher, Garcia-Alamino, Gardiner, Gardiner, Go, Hallan, Havrda, Hemkens, Heneghan, Heneghan, Hentrich, Higgins, Hobbs, Horstkotte, Horstkotte, Horstkotte, Hylek, Jackson, Jones, Jones, Jowett, Kannel, Khan, Kind, Kitchen, Koertke, Koertke, Koertke, Kvidal, Körtke, Körtke, Lafata, Lee, Marini, Matchar, Matchar, Matchar, McCahon, Menéndez-Jándula, Moher, Moon, Muller, Murray, Paioni, Pollack, Rasmussen, Regier, Robinson, Rose, Ruel, Ryan, Ryan, Ryan, Saka, Sawicki, Sawicki, Schmidt, Sidhu, Siebenhofer, Siebenhofer, Slot, Sobieraj-Teague, Sola-Morales, Soliman Hamad, Spackman, Sudlow, Sullivan, Sundberg, Sunderji, Sunderji, Taborski, Tamayo, Vahanian, van, Verret, Visnansky, Voller, Völler, Wallentin, Wallentin, Wang, Wardlaw, Wells, Williams, You   +145 more
core   +1 more source

Outcomes Associated With Oral Anticoagulants Plus Antiplatelets in Patients With Newly Diagnosed Atrial Fibrillation. [PDF]

, 2020
Importance: Patients with nonvalvular atrial fibrillation at risk of stroke should receive oral anticoagulants (OAC). However, approximately 1 in 8 patients in the Global Anticoagulant Registry in the Field (GARFIELD-AF) registry are treated with ...
Bassand, J-P, Camm, AJ, Dabrowski, E, Fitzmaurice, DA, Fox, KAA, GARFIELD-AF Investigators, Gersh, BJ, Gibbs, L, Goldhaber, SZ, Goto, S, Haas, S, Kakkar, AK, Luo, K, Misselwitz, F, Pieper, KS, Turpie, AGG, Velentgas, P, Verheugt, FWA   +17 more
core   +2 more sources

Falls and Traumatic Brain Injury in the Elderly on Aspirin or Anticoagulant Therapy [PDF]

, 2020
Introduction: Traumatic brain injury (TBI) after a fall in individuals aged 65 and older is a leading cause of morbidity and mortality, but the effect of aspirin and anticoagulant therapy on TBI severity is not fully understood.
Bassig, Jonathan, Miller, Stanton, Nauheim, David, Williams, Patricia, Zhan, Tingting   +4 more
core   +1 more source

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial [PDF]

, 2019
Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage.
Al-Shahi Salman, Rustam, Baigent, Colin, Dennis, M S, Lasserson, Daniel, Murray, G D, Newby, D E, others,, Rajkumar, Chakravarthi, RESTART Collaboration,, Sandercock, P A G, Sprigg, N, Stephen, J, Sudlow, C L M, Wardlaw, J M, Werring, D J, White, P M, Whiteley, W N   +16 more
core   +1 more source

Machine learning-assisted search for novel coagulants: when machine learning can be efficient even if data availability is low [PDF]

J. Comput. Chem. 45, No. 13, 937-952 (2024)
Design of new drugs is a challenging process: a candidate molecule should satisfy multiple conditions to act properly and make the least side-effect -- perfect candidates selectively attach to and influence only targets, leaving off-targets intact. The amount of experimental data about various properties of molecules constantly grows, promoting data ...
arxiv   +1 more source